TORONTO, ONTARIO--(Marketwire - February 27, 2008) - Cannasat Therapeutics (TSX VENTURE: CTH), the developer of novel cannabinoid-based pharmaceutical products, announced that it has received a favorable decision from the United States Patent and Trademark Office (USPTO).
